摘要
Abstract
Non-alcoholic fatty liver disease(NAFLD)is the most common liver disease worldwide,now renamed as metabolism-associated fatty liver disease(MAFLD).The incidence of NAFLD is increasing year by year worldwide,and delayed treatment may gradually progress to hepatitis,liver fibrosis,and cirrhosis.However,there are no officially ap-proved drugs on the market in China,so therapeutic drugs for this disease have become a hot issue.Current global thera-peutic studies for NAFLD include,but are not limited to,dietary and lifestyle interventions,vitamin E,statin lipid-lower-ing drugs,GLP-1 receptor agonists,SGLT2 inhibitors,PPAR agonists,ACC inhibitors,FGF19/21 inhibitors,farnesol X receptor agonists,probiotics,and thyroid β agonists,etc.In March,2024,Resmetirom was approved for marketing by the U.S.Food and Drug Administration(FDA)for the treatment of adult patients with non-alcoholic hepatitis with interme-diate to advanced liver fibrosis in combination with diet and exercise.Although Resmetirom is not available in China,it provides hope for the treatment of this disease.关键词
非酒精性脂肪性肝病/非酒精性脂肪性肝炎/维生素E/降脂药物Key words
non-alcoholic fatty liver disease/non-alcoholic steatohepatitis/vitamin E/lipid-lowering drugs分类
医药卫生
